Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Is Complete Revascularization Really Necessary after AMI in the Elderly?

The population over 75 is growing gradually, which entails an increase in acute myocardial infarction (AMI) in this group. As we all know, it is fairly common for AMI to present with multivessel disease. 

¿Es necesaria la revascularización completa luego de un IAM en los adultos mayores?

It has been shown that younger patients will benefit from complete revascularization vs. a simple resolution of the culprit vessel. However, this matter has not been looked at exhaustively in older patients and we lack data from large randomized studies in this regard. 

The FIRE Trial is a prospective randomized study designed to assess a physiology guided complete revascularization vs. culprit vessel revascularization in STEMI or N-STEMI patients over 75. It included a total 725 patients undergoing culprit only revascularization and 720 patients undergoing physiology guided complete revascularization (RCGF).

Primary end point was a composite of death, MI, stroke or ischemia driven revascularization within a year after randomization.

The two groups of patients had similar characteristics. Mean age was 80, and 36.5% were women. Also, 82% had hypertension, 32% diabetes, 15% prior MI, 18% prior PCI, 14% presented atrial fibrillation, 17% peripheral vascular disease, 8% stroke and 46% had some degree of kidney failure. 

Read also: OCT-Guided PCTA: Does It Offer any Benefits?

65% of patients had a history of NSTEMI (non ST elevation MI), 28% had Killip-Kimball (KK) ≥2, and 49%mean ejection fraction.

The anterior descending was the most affected artery (45%), followed by the right coronary and the circumflex. The left main was seldom affected. Also, 30% of patients received two or more stents during procedure. 

Hospital stay was slightly higher in the complete revascularization group, though this difference did not reach statistical significance. 

Read also: TAVI-in-TAVI with Balloon-Expandable Valves.

Primary end point was lower in the complete revascularization group (15.7% vs 21%; hazard ratio, 0.73; CI 95% [CI], 0.57 to 0.93; P = 0.01). The number necessary to treat to prevent new primary end point was 19 patients. There were no significant differences in terms of cardiovascular death or MI separately (8.9% vs 13.5%; hazard ratio, 0.64; CI 95%, 0.47 to 0.88). Neither were there differences in stroke, bleeding or kidney failure.

Conclusion

In conclusion, patients over 75 with MI and multivessel disease undergoing physiology guided complete revascularization were at lower risk of presenting the composite of death, MI, stroke or any revascularization within a year vs. patients receiving culprit only PCI. 

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: Complete or Culprit-Only PCI in Older Patients with Myocardial Infarction.

Reference: S. Biscaglia, et al. N Engl J Med 2023;389:889-98.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

GLUCO-TAVI | Can Glucocorticoids Reduce the Need for Permanent Pacemaker Implantation After TAVI?

Despite the expansion of transcatheter aortic valve implantation (TAVI) indications, cardiac conduction disturbances (CCD) and the need for permanent pacemaker implantation (PPI) remain the...

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...